Form 4: Director Janet Haugen Boosts West Pharma Holdings

West Pharmaceutical Services Director Janet Haugen reported an acquisition of phantom stock units, increasing her beneficial ownership.

Summary

• Janet Haugen, a Director at West Pharmaceutical Services Inc. (WST), reported changes in her beneficial ownership of derivative securities.
• On September 30, 2025, she acquired 48 phantom stock units as part of a pre-arranged plan, with each unit valued at $262.33.
• Following this transaction, her total beneficial ownership of phantom stock units increased to 162.161 units.
• Her direct beneficial ownership of common stock remains at 1,319.348 shares, which includes 1,071 restricted stock units and dividend equivalents.
• The restricted stock units are scheduled to vest in full on the date of the next annual shareholder meeting.
• The phantom stock units will be settled by delivery of shares upon her termination as a director.

Sentiment

Score: 7

Explanation: The acquisition of additional equity-based compensation by a director is generally viewed positively as it aligns their interests with shareholders and indicates confidence in the company's future, even if it's part of a routine compensation plan.

Positives

• Director Janet Haugen increased her beneficial ownership through the acquisition of phantom stock units, signaling continued alignment with shareholder interests.
• The acquisition of 48 phantom stock units at $262.33 per unit demonstrates a commitment to the company's future performance.

Future Outlook

The vesting of restricted stock units is tied to the next annual shareholder meeting, and phantom stock units will be settled upon the director's termination, indicating future share distributions based on continued service.

Industry Context

Insider transactions, such as those reported in Form 4 filings, are a routine aspect of corporate governance across all industries, providing transparency into management and director holdings. These transactions are often part of compensation plans designed to align executive and director interests with long-term shareholder value.

Comparison to Industry Standards

• The acquisition of equity-based compensation, such as restricted stock units and phantom stock units, is a standard practice for compensating directors in publicly traded companies, aligning their incentives with company performance.
• This is consistent with corporate governance best practices seen in peers within the pharmaceutical services sector, such as Catalent, Inc. (CTLT) or Lonza Group AG (LONN.SW), where similar equity-based compensation structures are common for non-executive directors.

Stakeholder Impact

• Shareholders: Increased alignment of director interests with shareholder value through equity ownership.

Next Steps

• Vesting of 1,071 restricted stock units and dividend equivalents on the date of the next annual shareholder meeting.
• Settlement of phantom stock units by delivery of shares upon the reporting person's termination as a director.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of equity-based compensation by a director, which is a positive signal of alignment but does not provide new fundamental information to warrant a change in investment recommendation. It confirms ongoing director engagement and compensation structure but lacks data for a strong buy or sell signal.

Keywords

West Pharmaceutical Services, WST, Janet Haugen, Director, Insider Trading, Form 4, Phantom Stock Units, Restricted Stock Units, Beneficial Ownership, Corporate Governance